SCHEMBL197619

SCHEMBL197619

Clc1ccc(-c2nc3ccccc3[nH]2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.72
NPC1 O15118 10/20 0.72
GAA P10253 2/20 0.72
KDM4E B2RXH2 13/20 0.69
ALDH1A1 P00352 11/20 0.69
SMN1; SMN2 Q16637 7/20 0.69
HPGD P15428 6/20 0.69
TP53 P04637 4/20 0.69
HSD17B10 Q99714 4/20 0.69
MAPT P10636 4/20 0.69
POLB P06746 2/20 0.69
GFER P55789 1/20 0.69
PKN1 Q16512 1/20 0.66
PKN2 Q16513 1/20 0.66
KMT2A Q03164 3/20 0.65
MEN1 O00255 2/20 0.65
CYP3A4 P08684 1/20 0.65
MAPK1 P28482 1/20 0.65
FTO Q9C0B1 1/20 0.65
PKM P14618 3/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20445410 0.91 KDM4E (0.68) RAB9ANPC1GAAKDM4EALDH1A1
SCHEMBL3929438 0.91 KDM4E (0.60) RAB9ANPC1GAAKDM4EALDH1A1
SCHEMBL20445296 0.91 NPC1 (0.60) RAB9ANPC1GAAKDM4EALDH1A1
SCHEMBL28256337 0.91 NPC1 (0.66) RAB9ANPC1GAAKDM4EALDH1A1
SCHEMBL29386825 0.90 NPC1 (0.88) RAB9ANPC1GAAKDM4EALDH1A1
SCHEMBL2178266 0.90 NPC1 (0.88) RAB9ANPC1GAAKDM4EALDH1A1
SCHEMBL24295036 0.88 NPC1 (0.84) RAB9ANPC1GAAKDM4EALDH1A1
SCHEMBL3928063 0.88 RAB9A (0.57) RAB9ANPC1GAAKDM4EALDH1A1
SCHEMBL3926454 0.88 CHEK2 (0.64) RAB9ANPC1GAAKDM4EALDH1A1
SCHEMBL5677793 0.88 CHEK2 (0.62) RAB9ANPC1GAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115433929-B Organic solderability copper surface protective agent and preparation method thereof 深圳市豪龙新材料技术有限公司 2023-08-08 CN claimed
CN-115433929-A Organic weldable copper surface protective agent and preparation method thereof 深圳市豪龙新材料技术有限公司 2022-12-06 CN claimed
US-7470827-B2 Composition for the vapor phase dehydrohalogenation of 1,1,2-trihaloethane to 1,1-dihaloethylene and methods for preparing and using such composition PPG INDUSTRIES OHIO, INC. (US) 2008-12-30 US claimed
US-20080242902-A1 Composition For the Vapor Phase Dehydrohalogenation of 1,1,2-Trihaloethane To 1,1-Dihaloethylene and Methods For Preparing and Using Such Composition PPG INDUSTRIES OHIO, INC (US) 2008-10-02 US claimed
EP-0251760-B1 Rubber composition BRIDGESTONE CORP (JP) 1994-01-26 EP claimed
US-5140055-A Improved high speed grip performance BRIDGESTONE CORPORATION (JP) 1992-08-18 US claimed
US-12403128-B2 Compositions and methods for blocking sodium channels Univerity of Virginia Patent Foundation (US) 2025-09-02 US disclosed
US-12195432-B2 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-01-14 US disclosed
CN-118440272-A Thiophene-triazinyl flexible D-A covalent organic framework material, preparation method and application 天津大学 2024-08-06 CN disclosed
WO-2024137505-A2 METHOD OF IMPROVING CELL FITNESS IN AN EX-VIVO CELL POPULATION TRANQUIS THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
CN-117603421-A Perylene bisimide covalent organic framework material and preparation method and application thereof 天津大学浙江研究院(绍兴) 2024-02-27 CN disclosed
CN-114989094-B Method for synthesizing benzimidazole derivative by visible light catalysis 云南民族大学 2023-09-29 CN disclosed
CN-116635028-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2023-08-22 CN disclosed
EP-0871442-A1 BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1998-10-21 EP disclosed
WO-1997025041-A1 BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-07-17 WO disclosed
EP-0251760-B1 Rubber composition BRIDGESTONE CORP (JP) 1994-01-26 EP disclosed
US-5140055-A Improved high speed grip performance BRIDGESTONE CORPORATION (JP) 1992-08-18 US disclosed
EP-0479161-A1 Synthesis of heterocyclic compounds EASTMAN CHEMICAL COMPANY (US) 1992-04-08 EP disclosed
EP-0251760-A2 Rubber composition Bridgestone Corporation (JP) 1988-01-07 EP disclosed
US-3953600-A HYPOLIPIDEMIC AGENTS SANDOZ, INC. (US) 1976-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12403128-B2 Compositions and methods for blocking sodium channels SCN3A, SCN1B, SCN2B RAB9A 2068/4885NPC1 483/4885GAA 1051/4885
US-12195432-B2 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases PPARG, PPARA, PPARD RAB9A 2214/4885NPC1 989/4885GAA 382/4885
US-20080242902-A1 Composition For the Vapor Phase Dehydrohalogenation of 1,1,2-Trihaloethane To 1,1-Dihaloethylene and Methods For Preparing and Using Such Composition CYP2E1, CYP1A1, HDHD5 RAB9A 3877/4885NPC1 2698/4885GAA 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.